A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Intranasal INNA-051 for Prevention of COVID-19 in Adults Following Close Contact With Individuals With SARS-CoV-2 Infection.
Latest Information Update: 15 Apr 2022
At a glance
- Drugs INNA-051 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ena Respiratory
- 07 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 15 Mar 2022 According to an Ena Respiratory media release, the study is expected to begin shortly.
- 11 Nov 2021 Status changed from planning to not yet recruiting.